Post Content
Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement expected to yield approximately $110 million in gross proceeds. The financing involves the sale of 9,481,000 shares of common stock at $9.50 per share, along with pre-funded warrants for an additional 2,106,000 shares.
The offering saw significant participation from a mix of new and existing institutional investors, including RA Capital Management, Adage Capital Partners, and Cormorant Asset Management. Leerink Partners and Piper Sandler served as the lead placement agents for the deal. As part of the agreement, the company committed to filing a registration statement with the SEC within 45 days of closing to allow for the resale of these securities.
While the specific use of proceeds was not detailed in the announcement, the capital injection strengthens Climb Bio Inc.’s (NASDAQ:CLYM) financial position as it advances its therapeutic pipeline. The shares and warrants were issued via a private placement exempt from standard registration requirements under the Securities Act of 1933.
Climb Bio Inc. (NASDAQ:CLYM) is a clinical-stage biotech company focused on developing therapies for immune-mediated diseases, with a pipeline centered on monoclonal antibodies targeting B-cell-driven conditions.
While we acknowledge the potential of CLYM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.